Deuruxolitinib

Deuruxolitinib is a deuterated form of [ruxolitinib] that selectively inhibits Janus kinases (JAK) JAK1 and JAK2. Deuteration allows the drug to circumvent extensive oxidative metabolism around the cyclopentyl ring, which increases the duration of the pharmacological activity of deuruxolitinib. On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata. Alopecia areata is an autoimmune condition that attacks the hair follicles and leads to unpredictable hair loss in the scalp and other areas of the body. The Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway has been implicated in the pathophysiology of alopecia areata, as it regulates the expression of inflammatory mediators. Deuruxolitinib works to block the inflammatory responses caused by JAKs. It is grouped under the following drug class(es): JAK inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Deuruxolitinib-d8 and D8-ruxolitinib. Its PubChem CID is 72704611.